288 related articles for article (PubMed ID: 17626792)
1. RGS10-null mutation impairs osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulation.
Yang S; Li YP
Genes Dev; 2007 Jul; 21(14):1803-16. PubMed ID: 17626792
[TBL] [Abstract][Full Text] [Related]
2. RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts in vitro.
Yang S; Li YP
J Bone Miner Res; 2007 Jan; 22(1):45-54. PubMed ID: 17042716
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Specificity of RGS10A as a key component in the RANKL signaling mechanism for osteoclast differentiation.
Yang S; Chen W; Stashenko P; Li YP
J Cell Sci; 2007 Oct; 120(Pt 19):3362-71. PubMed ID: 17881498
[TBL] [Abstract][Full Text] [Related]
5. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
6. Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts.
Komarova SV; Pereverzev A; Shum JW; Sims SM; Dixon SJ
Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2643-8. PubMed ID: 15695591
[TBL] [Abstract][Full Text] [Related]
7. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
[TBL] [Abstract][Full Text] [Related]
8. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
9. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
10. Homer2 and Homer3 modulate RANKL-induced NFATc1 signaling in osteoclastogenesis and bone metabolism.
Son A; Kang N; Oh SY; Kim KW; Muallem S; Yang YM; Shin DM
J Endocrinol; 2019 Sep; 242(3):241-249. PubMed ID: 31319381
[TBL] [Abstract][Full Text] [Related]
11. NADPH oxidase gp91
Kang IS; Kim C
Sci Rep; 2016 Nov; 6():38014. PubMed ID: 27897222
[TBL] [Abstract][Full Text] [Related]
12. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
[TBL] [Abstract][Full Text] [Related]
13. Orostachys japonicus Suppresses Osteoclast Differentiation by Inhibiting NFATc1 Expression.
Shim KS; Ha H; Kim T; Lee CJ; Ma JY
Am J Chin Med; 2015; 43(5):1013-30. PubMed ID: 26205967
[TBL] [Abstract][Full Text] [Related]
14. Lyn inhibits osteoclast differentiation by interfering with PLCgamma1-mediated Ca2+ signaling.
Yoon SH; Lee Y; Kim HJ; Lee ZH; Hyung SW; Lee SW; Kim HH
FEBS Lett; 2009 Apr; 583(7):1164-70. PubMed ID: 19285079
[TBL] [Abstract][Full Text] [Related]
15. Identification of LRRc17 as a negative regulator of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation.
Kim T; Kim K; Lee SH; So HS; Lee J; Kim N; Choi Y
J Biol Chem; 2009 May; 284(22):15308-16. PubMed ID: 19336404
[TBL] [Abstract][Full Text] [Related]
16. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation.
Negishi-Koga T; Takayanagi H
Immunol Rev; 2009 Sep; 231(1):241-56. PubMed ID: 19754901
[TBL] [Abstract][Full Text] [Related]
17. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
[TBL] [Abstract][Full Text] [Related]
20. Zinc inhibits osteoclast differentiation by suppression of Ca2+-Calcineurin-NFATc1 signaling pathway.
Park KH; Park B; Yoon DS; Kwon SH; Shin DM; Lee JW; Lee HG; Shim JH; Park JH; Lee JM
Cell Commun Signal; 2013 Oct; 11():74. PubMed ID: 24088289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
